Podcast: The Global Generics & Biosimilars Awards 2024

All The Details Of Our Latest Ceremony, This Year Taking Place On 9 October In Milan

In a podcast discussion, Generics Bulletin’s editors talk about how you can enter and attend the Global Generics & Biosimilars Awards, what makes for a good entry, and why companies and individuals will want to get involved in the event.

Generic Bulletin Podcast
The GGB Awards 2024 will take place on 9 October in Milan

The Global Generics & Biosimilars Awards is now in its eleventh year. In this podcast, Generics Bulletin editors Dave Wallace and Dean Rudge talk about how you can enter and attend the awards – both of which remain free of charge – as well as offering tips for entries and discussing the reasons why off-patent industry players might want to be involved in the event. 

Citeline · 2024 Global Generics & Biosimilars Awards

Open Media

Entries for the Global Generics & Biosimilars Awards 2024 are open until Monday 22 July and can cover any activities undertaken between 1 September 2023 and 31 July 2024. Our prizegiving ceremony will then take place in-person at the Hotel NH Milano Fiera on Wednesday 9 October, during CPhI Worldwide week.

Backed by headline sponsor IQVIA, category sponsors include Cerba Research for Company of the Year – Americas, as well as Pharmacloud for our Leader of the Year category.

The awards are also supported by International Health Partners in our corporate social responsibility initiative of the year category. Our 2024 supporters also include the International Generic and Biosimilars Medicines Association.

For a full list of the awards categories, submissions criteria, how to attend and other information, go here.

To enquire about sponsorship opportunities, please e-mail Casey.Burwell@citeline.com

And to register interest in attending the Global Generics & Biosimilars Awards 2024, to receive the latest updates and for any further details, please e-mail Jo.Kirkpatrick@citeline.com

More from Generics

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

BGMA Becomes Medicines UK

 
• By 

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By 

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

Iconovo Slims Down As It Focuses On Commercialization

 
• By 

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

More from Products

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By 

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By 

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

What’s Next? Five Things To Look Out For In May

 
• By 

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.